利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

44 条记录 (耗时 0.02 秒)

    DIRECT ASSAY OF THIOREDOXIN REDUCTASE ACTIVITY
    2.
    发明申请
    DIRECT ASSAY OF THIOREDOXIN REDUCTASE ACTIVITY 审中-公开
    直接测定噻托酮氧化还原酶活性

    公开(公告)号：US20150050682A1

    公开(公告)日：2015-02-19

    申请号：US14460759

    申请日：2014-08-15

    申请人： University of Vermont and State Agricultural College

    发明人： Robert J. Hondal ,  Nicholas H. Heintz ,  Brian Cunniff ,  Nicholas Fredette ,  Gregg W. Snider

    IPC分类号： C12Q1/26

    CPC分类号： C12Q1/26 ,  G01N2333/90212

    摘要： Provided is a direct method for detecting thioredoxin reductase (TR) activity in test samples. The method can provide a continuous and real-time measurement of TR activity. The method comprises contacting the test sample with NADPH and a diselenide substrate of TR, and then measuring conversion of NADPH to NADP. Also provided are kits for use in the method of direct detection of TR activity.

    摘要翻译： 提供了一种在测试样品中检测硫氧还蛋白还原酶（TR）活性的直接方法。 该方法可以提供TR活动的连续和实时测量。 该方法包括将测试样品与NADPH和二硒化物底物TR接触，然后测量NADPH向NADP的转化。 还提供了用于直接检测TR活性的方法的试剂盒。

    Compositions and methods of use of compounds to increase cancer patient survival time
    3.
    发明申请
    Compositions and methods of use of compounds to increase cancer patient survival time 有权
    使用化合物增加癌症患者生存时间的组合物和方法

    公开(公告)号：US20090232827A1

    公开(公告)日：2009-09-17

    申请号：US12218470

    申请日：2008-07-15

    申请人： Frederick H. Hausheer

    发明人： Frederick H. Hausheer

    IPC分类号： A61K39/395 ,  A61K31/105 ,  A61K31/095 ,  A61K31/505 ,  A61K31/7064 ,  A61K31/7076 ,  A61K31/337 ,  A61K31/282 ,  C12Q1/02 ,  A61P35/00 ,  C12Q1/68 ,  A61K33/24 ,  A61K31/704 ,  A61K31/437 ,  A61K38/43 ,  A61K38/16 ,  A61K38/02

    CPC分类号： A61K33/24 ,  A61K31/095 ,  A61K31/105 ,  A61K31/282 ,  A61K31/337 ,  A61K31/437 ,  A61K31/505 ,  A61K31/704 ,  A61K31/7064 ,  A61K31/7076 ,  A61K38/05 ,  A61K38/06 ,  A61K45/06 ,  G01N33/57407 ,  G01N2333/90212 ,  A61K2300/00

    摘要： The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

    摘要翻译： 本发明公开并要求组合物，治疗方法和试剂盒，其导致癌症患者的存活时间增加，其中所述癌症或者：（i）过表达硫氧还蛋白或谷氧还蛋白和/或（ii）显示硫氧还蛋白或 对一种或多种化学治疗干预的谷氧还蛋白介导的抗性。 本发明还公开并要求用于施用所述组合物以适当治疗癌症患者的方法和试剂盒。 此外，本发明公开并说明了用于定量测定癌症患者癌细胞中硫氧还蛋白或谷氧还蛋白表达水平的方法和试剂盒，在初始诊断和/或规划后续治疗方法中使用确定水平的方法 所述癌症患者以及确定特定癌症的潜在增长“侵略性”和特定类型癌症的治疗反应性。 此外，本发明公开并要求用于治疗患有硫氧还蛋白和/或谷氧还蛋白过表达的医学病症和疾病的患者的新型药物组合物，方法和试剂盒，并且其中所述过表达与有害的生理作用相关 病人。

    High specificity homocysteine assays for biological samples
    8.
    发明授权
    High specificity homocysteine assays for biological samples 失效

    公开(公告)号：US5998191A

    公开(公告)日：1999-12-07

    申请号：US122129

    申请日：1998-07-24

    申请人： Yuying Tan ,  Martin Lenz

    发明人： Yuying Tan ,  Martin Lenz

    IPC分类号： C12N15/09 ,  C12N1/21 ,  C12N9/02 ,  C12N9/10 ,  C12N9/14 ,  C12Q1/25 ,  C12Q1/34 ,  C12Q1/527 ,  C12Q1/68 ,  C12R1/19 ,  G01N33/68 ,  C12N9/86 ,  C07H21/04 ,  C07K1/00 ,  C12Q3/00

    CPC分类号： C12N9/0051 ,  C12N9/13 ,  C12Q1/527 ,  G01N33/6815 ,  C07K2319/00 ,  G01N2333/90212 ,  G01N2333/91194

    摘要： Novel enzymatic methods to determine the concentration of homocysteine in biological fluids are described. In a typical embodiment of the invention, the biological fluid sample is from a patient, and the methods of the invention are useful to assess risk for cardiovascular disease. The novel methods of the invention involve use of particular homocysteinase enzymes that permit the determination of homocysteine concentrations in biological samples without interference from the concentrations of cysteine and/or of methionine that are routinely present in such samples. There is also provided a diagnostic kit for use in determining the amount of homocysteine in a biological sample comprising (a) a homocysteinase having the aformentioned characteristics, and (b) at least one reagent capable of being used to determine the amount of product formed in the homocysteinase reaction. In a further aspect, the homocysteinase is provided as a chimeric molecule that comprises amino acid subsequences derived from, or patterned on, more than one homocysteinase, and which is typically produced from a chimeric polynucleotide that encodes therefor. Additional enhancements in homocysteine assay methodology include use of the enzyme .gamma.-glutamylcysteine synthetase to further limit any interference from cysteine present in the biological samples.